Minerva Neurosciences, Inc. — Q1 2020 Form 10-Q
Business context and period: Clinical-stage biopharmaceutical company developing CNS treatments, including roluperidone for schizophrenia, seltorexant with Janssen for insomnia and major depressive disorder (MDD), and MIN-301 for Parkinson’s disease. The unaudited quarter ended March 31, 2020; comparisons are with Q1 2019 unless noted. The company had no approved products and no product-sale revenue.
Financial performance and position
- Revenue and margins: No product-sale revenue was reported. The $41.2 million deferred-revenue balance relates to Janssen collaboration consideration and is recognized as qualifying services are performed; it is not current-quarter product revenue. Profit margins are not meaningful for this pre-commercial company.
- Operating results: R&D expense was $8.1 million, down from $11.6 million; G&A was $4.2 million, down from $4.7 million. Total operating expenses were $12.3 million, versus $16.3 million. Net loss was $12.2 million, or $0.31 per share, compared with $15.8 million, or $0.41 per share.
- Cash flow: Operating cash use was $9.2 million, compared with $9.6 million. Investing activities provided $17.0 million, primarily from maturities and redemptions of securities; financing provided $0.8 million from stock-option exercises. Cash, cash equivalents and restricted cash increased by $8.6 million to $30.1 million.
- Liquidity: Cash, cash equivalents, restricted cash and marketable securities totaled $37.6 million at March 31, 2020, versus $46.0 million at December 31, 2019. Current assets were $38.5 million and current liabilities $7.1 million. Management said existing funds should cover cash commitments for at least 12 months after issuance of the statements, but additional capital will be needed to continue operations and fund later-stage development.
- Debt and equity: No borrowings were reported on the balance sheet; the former term loans were repaid in 2018. Stockholders’ equity was $18.6 million, down from $27.8 million at year-end, and accumulated deficit was $298.9 million. Shares outstanding at March 31 were 39.2 million.
Material changes and developments
- Lower R&D expense reflected reduced spending on the roluperidone Phase 3 and MIN-117 Phase 2b trials. Management expected R&D spending to decrease during 2020 as MIN-117 work had ended and the 12-week double-blind portion of the roluperidone trial approached completion.
- Lower G&A expense primarily reflected reduced stock-based compensation and professional fees. Investment income fell to $0.1 million from $0.5 million.
- MIN-117’s Phase 2b MDD trial failed its primary and key secondary endpoints; the company said it had no plans for further MDD development. The related $19.0 million IPR&D impairment was recorded in 2019, not Q1 2020.
Outlook, risks and contingencies
- Roluperidone: The Phase 3 trial had randomized 515 patients. As of April 30, 2020, 362 had completed the double-blind phase, 333 had entered the extension, and 92 had completed it. The company continued to expect top-line results from the 12-week phase in Q2 2020. COVID-19-related site access, travel and medication disruptions could affect retention in the extension or delay development.
- Janssen dispute: The parties disagreed over whether contractual Decision Point 4 had been reached, which determines when Minerva’s cost-sharing obligations begin. Janssen invoiced $3.4 million in January and a further $3.1 million in April, totaling $6.5 million through March 31. Minerva had not accrued these Phase 3 costs. Janssen had indicated it might incur approximately $100 million in Phase 3 costs during 2020. A significant payment could exceed available resources and require new financing; the company was in discussions with Janssen.
- Seltorexant: Prior Phase 2 results included positive insomnia findings and mixed MDD results. Janssen’s proposed Phase 3 program and Minerva’s strategic-control rights remained under discussion, with consultation with regulators ongoing. Timing and COVID-19 effects on the preliminary Phase 3 program were uncertain.
- MIN-301: Preclinical work continued toward an IND or equivalent filing; a Phase 1 study was expected thereafter. This was a forward-looking plan, not a disclosed filing or trial start.
- Funding and development risks: The company expects continuing losses and negative operating cash flow, has no commercial products, and said additional financing may be unavailable or dilutive. Failure to obtain funding could require development to be scaled back or discontinued. COVID-19 could disrupt trials, operations and access to capital.
- Other disclosures: Management reported effective disclosure controls as of March 31, 2020 and no material change in internal control over financial reporting. The filing reported no material legal proceeding and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether roluperidone’s Phase 3 top-line results were delivered as expected and what they showed.
- How the Janssen Decision Point 4 dispute was resolved, including payment exposure and any effect on seltorexant development rights or costs.
- Cash burn, financing needs and actual runway, particularly if Janssen seeks reimbursement or clinical spending changes.
- COVID-19 effects on roluperidone extension retention, clinical timelines and the proposed seltorexant program.
- Whether MIN-301 advances to clinical testing and whether any further development plans change for the company’s other candidates.